Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF)

Pathologie Biologie

Volumn 55, Issue 2, 2007, Pages 92-104

  Michiels, J J ^a,b   Bernema, Z ^a   Van Bockstaele, D ^a   De Raeve, H ^a   Schroyens, W ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Goodheart Institute   (Netherlands)

Author keywords

Bone marrow pathology; Endogenous erythroid colony assay; Erythropoietin; Essential thrombocythemia; JAK2 V617F mutation; Myelofibrosis; Myeloid metaplasia; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

ALKALINE PHOSPHATASE; ERYTHROPOIETIN; JANUS KINASE 2; MOLECULAR MARKER;

ARTICLE; BONE MARROW CELL; CELL GROWTH; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROID CELL; GENE MUTATION; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PROGNOSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPLANCHNIC BLOOD FLOW; SPLENOMEGALY; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

AMINO ACID SUBSTITUTION; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BONE MARROW; CELL LINEAGE; COLONY-FORMING UNITS ASSAY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE VOLUME; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN; HUMANS; ISOANTIGENS; JANUS KINASE 2; MEMBRANE GLYCOPROTEINS; MUTATION, MISSENSE; MYELOFIBROSIS; MYELOID METAPLASIA; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA, HEMORRHAGIC; WORLD HEALTH ORGANIZATION;

EID: 33947212881     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.06.002     Document Type: Article

References (108)

1. Dameshek W. Physiopathology and course of polycythemia vera as related to therapy. J Am Ass Med 142 (1950) 790-797
2. James C., Ugo V., Casadevall N., Constantinescu S.N., and Vainchenker W.A. JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med (2005) (On line)
3. Wasserman L.R. Polycthemia vera, its course and treatment: relation to myeloid metaplasia and leukemia. Bull. N. Y. Acad. Med. 30 (1954) 343-375
4. Wasserman L.R., and Berk P.D. Berlin NI. Polycythemia vera and the myeloproliferative disorders (1995), WB Saunders, Philadelphia (ISBN 0-7216-4213-6)
5. Pearson T.C., and Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin. Lab. Haematol. 1 (1979) 189-196
6. Najean Y., Triebel F., and Dresch C. Pure erythrocytosis: reappraisal of a study of 51 patients. Am. J. Hematol. 10 (1981) 129-136
7. Glaser R.M., and Walker R.I. Transitions among the myeloproliferative disorders. Ann. Intern. Med. 71 (1969) 285-307
8. Burkhardt R., Bartl R., Jaeger K., Frisch B., Kettner G., Mahl G., Sund M. Chronic myeloproliferative disorders. Path Res Pract 1084;179:131-186.
9. Georgii A., Vykoupil K.F., and Thiele J. Chronic megakaryocytic granulocytic myelosis: CMGM. Virch Arch A Path Anat Histol 389 (1980) 253-268
10. Georgii A., Vykoupil K.F., Buhr T., Choritz H., Doehler U., Kaloutsi V., and Werner M. Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract 186 (1990) 3-27
11. Georgii A., Buhr T., Buesche G., Kreft A., and Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk. Lymphoma 22 Suppl 1 (1996) 15-29
12. Georgii A., Buesche G., and Kreft A. The histopathology of chronic myeloproliferative diseases. Bailière's Clin Haematol 11 (1998) 721-749
13. Thiele J., Ballard A.C., Georgii A., and Vykoupil K.F. Chronic megakaryocytic granulocytic myelosis: An electron microscopic study. Megakaryocytes and thrombocytes. Virch Arch 373 (1977) 191-211 (Path Anat Histol)
14. Thiele J., Holgado S., Choritz H., and Georgii A. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative disorders. Scand. J. Haematol. 31 (1983) 329-341
15. Thiele J., Zankovich R., Schneider G., Kremer B., Fischer R., and Diehl V. Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies. Analyt Quat Cytol Histol 10 (1988) 375-382
16. Thiele J., Zankovich R., Steinberg T., Kremer B., Fischer R., and Diehl V. Primary (essential) thrombocythemia versus hyperplastic stages of agnogenic myeloid metaplasia with thrombocytosis: a critical evaluation of clinical and histomorphological data. Acta Haematol. 81 (1989) 192-202
17. Thiele J., Wagner S., Degel C., et al. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. Virch Arch 58 (1990) 295-302 (Cell Pathol)
18. Thiele J., Kvasnicka H.M., Werden C., Zankovich R., Diehl V., and Fischer R. Idiopathic primary osteo-myelofibrosis: A clinico-pathological study on 208 patients wit special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk. Lymphoma 22 (1996) 303-317
19. Michiels J.J. The myeloproliferative disorders. An historical appraisal and personal experiences. Leuk. Lymphoma 22 Suppl 1 (1996) 1-14
20. Michiels J.J. Diagnostic criteria of the myeloproliferative disorders (MPD) essential thrombocythemia, polycythemia vera and chronic megakaryocytic granulocytic metaplasia. Neth. J. Med. 51 (1997) 57-64
21. Michiels J.J., and Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemostas 23 (1997) 339-347
22. Thiele J., Kvasnicka H.M., and Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders: aids to diagnosis and classification. Ann Hematol 78 (1999) 495-506
23. Thiele J., Kvasnicka H.M., Diehl V., Fischer R., and Michiels J.J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk. Lymphoma 33 (1999) 207-218
24. WHO classification of the chronic myeloproliferative diseases (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. WHO Classification of Tumours. Tumours of Haemtopoiesis and Lymphoid Tissues (2001), IARC, Lyon 31-42
25. Michiels J.J., and Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int. J. Hematol. 76 (2002) 133-145
26. Michiels J.J. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic myeloid metaplasia. Hematol. J. 5 (2004) 93-102
27. Thiele J., Kvasnicka H.M., Boeltken B., Zankovich R., Diehl V., and Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF): a clinicopathological study. Leukemia 13 (1999) 1741-17428
28. Thiele J., Kvasnika H.M., Zankovich R., and Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematlogica 85 (2000) 1126-1134
29. Thiele J., Kvasnicka H.M., Zankovich R., and Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann. Hematol. 80 (2001) 160-165
30. Thiele J., Kvasnicka H.M., Zankovich R., and Diehl V. Early stage idiopathic (primary) myelofibrosis: current issues of diagnostic features. Leuk. Lymphoma 43 (2002) 1036-1041
31. Thiele J., and Kvasnicka H.M. Diagnostic differentiation of essential thrombocythemia from thrombocythemia associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features. Histol. Histopathol. 18 (2003) 93-102
32. Thiele J., Kvasnicka H.M., Schmitt-Graeff A., and Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up on 308 patients. Leuk. Lymphoma 44 (2003) 949-953
33. Thiele J., and Kvasnicka H.M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classifications systems (PVSG-WHO) on 839 patients. Ann. Hematol. 82 (2003) 148-152
34. Thiele J., and Kvasnicka H.M. Prefibrotic chronic myelofibrosis - a diagnostic enigma?. Acta Haematol. 111 (2004) 155-159
35. Thiele J., Kvasnicka H.M., and Diehl V. Standadization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns?. Histopathol 20 (2005) 633-644
36. Thiele J., Kvasnicka H.M., and Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approacj. Semin. Hematol. 42 (2005) 184-195
37. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD and hemorrhagic thrombocythemia. Semin. Hematol. 12 (1975) 409-432
38. Murphy S., Iland H., Rosenthal D., and Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin. Hematol. 23 (1986) 177-182
39. Berlin N.I. Diagnosis and classification of the polycythemias. Sem Hematol 12 (1975) 339-351
40. Thiele J., Kvasnicka H.M., Zankovich R., and Diehl V. The value of bone marrow histopathology for the differentiation between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 86 (2001) 368-374
41. Thiele J., Kvasnicka H.M., Muehlhausen K., Walter S., Zankovich R., and Diehl V. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol. Res. Pract. 197 (2001) 77-84
42. Thiele J., Kvasnicka H.M., and Diehl V. Bone marrow features of diagnostic impact in erythrocytosis. Ann Haematol 84 (2005) 362-367
43. Thiele J., Kvasnicka H.M., and Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 113 (2005) 213-219
44. Thiele J., and Kvasnicka H.M. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histpathol 20 (2005) 317-328
45. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin. Proc. 78 (2003) 174-194
46. McMullin M.F., Bareford D., Campell P., Green A.R., et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br. J. Haematol. 130 (2005) 174-195
47. De Stefano V., Teofili L., Leone G., and Michiels J.J. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemostas 23 (1997) 411-418
48. Chait Y., Condat B., Cazals-Hatem D., et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic vein thrombosis. Br. J. Haematol. 129 (2005) 553-560
49. Liu E., Jelinek J., Pastore Y.D., Guan Y., Prchal J.F., and Prchal J.T. Discrimination of polycythemias and thrombocythemias by novel, simple accurate clonality assays and comparison with PRV-1 expression and BFU:E response to erythropoietin. Blood 101 (2003) 3294-3301
50. Shih L.-Y., and Lee C.-T. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 83 (1994) 744-748
51. Westwood N.B., and Pearson T.C. Diagnostic applications of haematopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk. Lymphoma 22 (1996) 95-103
52. Dobo I., Donnard M., Giridon F., Mossuz P., et al. Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. Hematol. J. 5 (2004) 161-167
53. Florensa L., Besses C., Zamora L., Bellosillo B., Espinet B., Serrano S., et al. Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood 103 (2004) 2427-2428
54. Messinezy M., Westwood N.B., El-Hemaida I., Marsden J.T., Sherwood R.S., and Pearson T.C. Serum erythropoietin values in erythrocytosis and in primary thrombocythaemia. Br. J. Haematol. 117 (2002) 47-53
55. Cotes P.M., Dore C.J., Tin J.A., Lewis S.M., Messinezy M., Pearson T.C., et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N. Engl. J. Med. 315 (1986) 283-287
56. Birgegard G., and Wide L. Serum erythropoietin in the diagnosis of polycythemia and after phlebotomy treatment. Br. J. Haematol. 81 (1992) 603-606
57. Messinezy M., Westwood N.B., Woodstock S.P., Strong R.M., and Pearson T.C. Low serum erythropoietin: a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin. Lab. Haematol. 17 (1995) 217-220
58. Carneskog J., Kutti J., Wadenvik H., Lundberg P.A., and Lindstedt G. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated patients with polycythemia vera and essential thrombocythemia. Eur. J. Haematol. 60 (1998) 278-282
59. Griesshammer M., Kubanek B., Beneke H., Heimpel H., Bangerter M., Bergmann L., and Shrezenmeier H. Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythemia. Leuk. Lymphoma 36 (2000) 533-538
60. Mossuz P., Giridon F., Latger-Cannoard V., Dobo I., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis (2004), Haematlogica 1194-1198
61. Temerinac S., Klippel S., Strunck E., Röder S., Lübbert M., Lange M., et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is over expressed in polycythemia rubra vera. Blood 95 (2000) 2569-2576
62. Pahl H.L. Towards a molecular understanding of polycythemia rubra vera. Eur. J. Biochem. 267 (2000) 3395-3401
63. Klippel S., Strunck E., Termerinac S., et al. Quantification of PRV-1 expression, a molecular marker for the diagnosis of polycythemia vera. Blood 98 (2001) 470a
64. Pahl H.L. Polycythaemia vera: will new markers help us answer old questions?. Acta Haematol. 108 (2002) 120-131
65. Johanson P., Andreason B., Safai-Kutti S., Wennstrom L., Palmqvist L., Rickson A., et al. The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythemia. Eur. J. Haematol. 70 (2003) 358-362
66. Griesshammer M., Klippel S., Strunk E., Temeric S., Mohr U., Heimpel H., et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann. Hematol. 83 (2004) 364-370
67. Juvonen E., Ikkala E., Oksanen K., and Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br. J. Haematol. 83 (1993) 192-197
68. Florensa L., Bessis C., Woessner S., Sole F., Acin P., Pedro C., et al. Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythemia. Leukemia 9 (1995) 271-273
69. Jantunen R., Juvonen E., Ikkala E., Oksanen K., Anttila P., Jormila P., et al. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings. Ann. Hematol. 77 (1998) 101-106
70. Reilly J.T. Pathogenesis of idiopathic myelofibrosis: present status and future directions. Br. J. Haematol. 88 (1994) 1-8
71. Tefferi A., Silverstein M.N., and Noël P. Agnogenic myeloid metaplasia. Semin. Hematol. 22 (1995) 327-333
72. Barosi G., Ambrosetti A., Finelli, et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 104 (1999) 730-737
73. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J. Clin. Oncol. 17 (1999) 2954-2970
74. Tefferi A. Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 342 (2000) 1255-1265
75. Dingli D., Mesa R.A., and Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern. Med. 43 (2004) 540-547
76. + progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders: a clinicopathological study on 575 patients. Leuk. Lymphoma 46 (2005) 709-715
77. Florena A.M., Tripodi C., Iannitto E., Porcasi R., Ingrao S., and Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 89 (2004) 911-919
78. Bauermeister D.E. Quantification of bone marrow reticulin. Am. J. Clin. Pathol. 56 (1971) 24-31
79. Manoharan A., Smart R.C., and Pitney W.R. Prognostic factors in myelofibrosis. Pathology 14 (1982) 445-461
80. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., Van Der Walt J., and Orazi A. European consensus for grading of bone marrow fibrosis and assessment of cellularity in myeloproliferative disorders. Haematologica 90 (2005) 1128-1132
81. Buhr T., Georgi A., and Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes to the Hannover Classification. Patol Res Pract 189 (1993) 121-132
82. Thiele J., Kvasnicka H.M., Schmitt-Graeff A., Zankovich R., and Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am. J. Hematol. 70 (2002) 283-291
83. Kreft A., Buesche G., Ghalibafian M., Buhr T., Fischer T., and Kirkpatrick C.J. The incidence of myelofibrosis in essential thrombocythemia, polycythemia vera and chronic idiopathicmyelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 113 (2005) 137-143
84. Thiele J., Kvanicka H.M., Schmitt-Graeff A., and Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk. Lymphoma 44 (2003) 949-953
85. Buhr T., Buesche G., Choritz H., Langer F., and Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am. J. Clin. Pathol. 119 (2003) 152-158
86. Thiele J., and Kvasnicka H.M. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin. Oncol. 32 (2005) 380-394
87. Michiels J.J., Kvasnicka H.M., and Thiele J. Myeloproliferative Disorders: current perspectives on diagnostic criteria, histopathology and treatment (2005), Verlag ME Uwe Grunwald, Munich Germany (ISBN 3-9898075-6-8)
88. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a bew scoring syste. Blod 88 (1996) 1013-1018
89. Reilly J.T. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 11 (1997) 233-242
90. Michiels J.J. Clinical, pathological and molecular features of myeloproliferative disorders: MPD 2005 and beyond. Hematology (Am Soc Hematol Educ Program) 10 Suppl 1 (2005) 215-223
91. James C., Ugo V., Le Couedic P.F., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 434 (2005) 1144-1148
92. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cells 7 (2005) 387-397
93. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
94. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
95. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz A.S., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 29 (2005)
96. Kaushanky K. On the origin of the chronic myeloproliferative disorders: it makes all sense. Blood 105 (2005) 4187-4190
97. Goldman J.M. A unifying mutation in chronic myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1744-1745
98. Cazzola M., and Skoda R. Gain of function, loss of control. A molecular basis for chronic myeloproliferative disorders. Haematologica Hematol J 90 (2005) 871-874
99. Jones A.V., Kreil S., Xoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
100. Wolanskyj A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., Lee S.J., et al. JAK2 V617 mutation in essential thrombocythaemia: clinical associations and long-term relevance. Br. J. Haematol. 131 (2005) 208-213
101. Antonioli E., Guglielmelli P., Pancrazzi A., Bogani C., Verrucci M., Ponziani V., et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19 (2005) 1847-1849
102. Goerttler P.S., Steimle C., Maerz E., Johanson P.L., Andreasson B., Griesshammer M., et al. The JAK2 V617F mutation, PRV-1 over expression and EEC formation define a similar cohort of MPD patients. Blood 106 (2005) 2862-2864
103. Kralovics R., Teo S.S., Buser A.S., et al. Altered gene expression in myeloproliferative disorders correlates with activation of signalling by the V617F mutation of JAK2. Blood 106 (2005) 3374-3376
104. Levine R.L., Loriaux M., Huntly B.J.P., Loh M.L., et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
105. Steensma D.P., Dewald M., Lasho T.L., Powell H.L., and McClure R.F. Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and the myelodysplastic syndrome. Blood 106 (2005) 1207-1209
106. Jelinek J., Oki Y., Gharibyan V., Bueso-Ramos C., Prchal J.T., Verstovsek S., et al. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood (2005) [Epub ahead of print]
107. Kiladjian JJ, Elkassar N, Hetet G, Balitrand N et al. Analysis of JAK2 mutation in essential thrombocythemia (ET) patients with monoclonal and polyclonal X-chromosome inactivation patterns (XCIPs). Blood (Suppl Abstract 807-II).
108. Campbell P., Scott L.M., and Buck G. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 9501 (2005) 1945-1953